PRMT5 and B-cell chronic lymphocytic leukemia: However, when compared with the SAM non-competitive PRMT5 inhibitor EPZ015666, PRT382 demonstrated superior in vitro anti-tumor activity and improved survival in the Eμ-PRMT5/TCL1 mouse model of CLL/RT in vivo.